5-Alpha reductase inhibitors in patients on active surveillance: Do the benefits outweigh the risk?

hopeful and optimistic
hopeful and optimistic Member Posts: 2,333 Member




Prostate cancer (PCa) is a slow, progressive disease.

Prostate specific antigen testing, screening, and aggressive case identification has made PCa the most frequently diagnosed cancer. Concerns regarding overdiagnosis and overtreatment flourish on a large scale. In order to avoid overtreatment for those in whom therapeutic intervention is not required, active surveillance for eligible patients with the use of 5-alpha reductase can be considered a safe and a promising approach to delay the progression of the disease with minimal side effects.

Written by: 
Al Edwan G, Fleshner N.   Are you the author? 
Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. [email protected]

Reference: Curr Urol Rep. 2013 Apr 12. Epub ahead of print. 
doi: 10.1007/s11934-013-0324-y

PubMed Abstract
PMID: 23579402

UroToday.com Prostate Cancer Section